MedTrace Logo

Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts

NCT01608243 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 94

Last updated 2014-07-01

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety of different doses of sublingual tablets of house dust mite allergen extracts in adults with house dust mite-associated allergic asthma.

Conditions

  • Asthma
  • House Dust Mite Allergy

Interventions

BIOLOGICAL

SLIT tablets of house dust mite allergen extracts

10 dosing days

BIOLOGICAL

Matching placebo

10 dosing days

Sponsors & Collaborators

  • Stallergenes Greer

    lead INDUSTRY

Principal Investigators

  • Pascal Demoly, MD · CHU Arnaud de Villeneuve, Montpellier, France

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-31
Primary Completion
2014-06-30
Completion
2014-06-30

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01608243 on ClinicalTrials.gov